{
    "nct_id": "NCT06287463",
    "official_title": "A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway",
    "inclusion_criteria": "General Inclusion Criteria ModA Part 1 and 2:\n\n* Able to take oral medication\n* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements\n* Adequate organ function and electrolytes\n* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1 at Screening\n* Has a life expectancy of more than 6 months\n* In addition to these general inclusion criteria, participants must meet all the module cohort-specific inclusion criteria\n\nInclusion Criteria ModA Part 1 Cohort Specific:\n\n* Pathologically confirmed diagnosis of solid cancer and documentation of Kirsten rat sarcoma (KRAS), Harvey rat sarcoma virus (HRAS), neuroblastoma ras viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-raf murine sarcoma viral oncogene homolog C1(CRAF), and/or neurofibromatosis 1 (NF1) mutation\n* Have exhausted all available standard of care therapies that are known to provide benefit for the participant's condition, as judged by the Investigator\n\nInclusion Criteria ModA Part 2 Cohort Specific:\n\n* Documented BRAF gene mutation\n* Pathologically confirmed diagnosis with PD after at least one prior line of therapy in the advanced or metastatic setting\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "General Exclusion Criteria ModA Part 1 and 2:\n\n* Prior treatment with certain BRAF dimer inhibitors\n* Female participant is pregnant or lactating\n* Received any prior or concurrent medications or therapies known to be prohibited with DCC-3084 within 14 days\n* Received any prior antitumor therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-3084\n* Known allergy or hypersensitivity to any component of the study drug\n* Invasive malignancy within 2 years prior to the first dose of study drug other than the study indication or specific types of cancer treated with curative intent\n* Have not recovered from all clinically relevant toxicities from prior therapy\n* Impaired cardiac function\n* History of recent thrombotic or embolic events\n* Malabsorption syndrome or other illness that could affect oral absorption\n* Major surgery within 28 days of the first dose of study drug\n* In addition to the general exclusion criteria, participants will also be excluded based on the cohort-specific exclusion criteria\n\nExclusion Criteria: Module A Part 2 Cohort Specific:\n\nâ€¢ Has known co-occurring mutation of KRAS, HRAS, NRAS, NF1, epidermal growth factor receptor, Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA), or Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN)",
    "miscellaneous_criteria": ""
}